|1.||Fukushima, Masakazu: 61 articles (01/2015 - 01/2002)|
|2.||Goldberg, Richard M: 59 articles (04/2015 - 03/2002)|
|3.||Nagano, Hiroaki: 44 articles (11/2014 - 01/2002)|
|4.||Boku, Narikazu: 43 articles (10/2015 - 01/2002)|
|5.||Van Cutsem, Eric: 39 articles (12/2015 - 04/2002)|
|6.||de Gramont, Aimery: 38 articles (12/2015 - 04/2002)|
|7.||Cunningham, D: 38 articles (06/2013 - 03/2000)|
|8.||Monden, Morito: 36 articles (02/2012 - 01/2002)|
|9.||André, Thierry: 35 articles (12/2015 - 01/2003)|
|10.||Shimada, Yasuhiro: 35 articles (09/2015 - 01/2002)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
01/01/1986 - "5-Fluorouracil as a single agent has shown the best results to date, and is the treatment of first choice but no treatment has been shown to prolong survival unequivocally in colorectal cancer. "
08/01/2000 - "Synergistic with 5-FU in colorectal cancer (CRC), the combination has proven efficacy in 5-FU-resistant advanced disease and in previously untreated CRC, as demonstrated in controlled phase III trials, while evaluation in the adjuvant setting is ongoing. "
04/01/1996 - "Although no optimal combination dose schedule of LV is well known, randomized studies have shown improved activity of 5-FU modulation by LV over 5-FU alone for advanced colorectal cancer doubled the response rate by monotherapy (20-25%) vs 10-15%). "
06/01/1995 - "From the present study, l-LV and 5-FU combination therapy seems to be a very promising and useful treatment for patients with advanced colorectal carcinoma."
10/01/2009 - "The MTHFR 677C>T and 1298A>C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C>T polymorphism may be associated with lower toxicity in 5-FU treatment. "
04/01/2004 - "Combined treatment with 5-FU and AxE1AdB-UPRT dramatically reduced the disseminated tumor burden without causing toxicity in normal tissues. "
06/30/2000 - "Effective treatment of certain cancers with 5-fluorouracil (5-FU) and irradiation is well established; however, the most effective combination of these agents remains controversial. "
09/01/1999 - "DPD activity is highly variable in cancer populations, and this variation may influence the antitumor efficacy of 5-fluorouracil. "
09/01/1987 - "To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer."
01/01/1996 - "Several studies suggest that protracted continuous infusion constitutes an important way to optimize the dose and the efficacy of 5-fluorouracil (5-FU) in metastatic cancer. "
|3.||Stomach Neoplasms (Stomach Cancer)
05/01/2003 - "Based on its remarkable effectiveness, marked improvement in the quality of life of the patients, and the convenience of its administration, the I/low-P regimen is recommended as a promising second-line chemotherapeutic regimen for patients with metastatic gastric cancer resistant to 5-FU."
09/01/1989 - "The fact that MMC, ADM, and 5-Fu are most effective in the treatment of gastric cancer suggests that the cell line MGc 80-3 may still retain its original drug sensitivity which is consistent with that noted in clinical gastric cancer. "
07/01/2015 - "S-1, a novel oral fluorouracil, has showed very effective in metastatic gastric cancer and became the standard option for gastric cancer with D2 dissection. "
04/01/1992 - "However, in gastric cancer, 5-FU/FA and 5-FU/IFN seem to induce higher complete and overall remission rates in advanced gastric cancer compared with 5-FU alone. "
06/01/1990 - "Thus, a randomized comparison of FAM with FAM-CF would not determine whether CF modulation increases the efficacy of 5-FU when it is administered in optimal doses to patients with gastric cancer."
|4.||Neoplasm Metastasis (Metastasis)
03/01/1995 - "When 5-fluorouracil was injected at a dose of 15 mg/kg/day every other day after the inoculation of tumour cells a highly significant reduction in the incidence of metastases was seen (compared with the controls). "
04/01/2000 - "This randomized study revealed that short term HAI of 5-FU after curative resection of colorectal hepatic metastases is effective in preventing the recurrence of disease without any serious complications."
10/01/2003 - "Arterial infusion therapy with 5-fluorouracil (5-FU) was given at 1,500 mg every 2 weeks up to a total dose of 37.5 g, resulting in complete remission (CR) of the liver metastases. "
09/01/1996 - "A total dose of 1,150 mg of MTX and 6,250 mg of 5-FU caused a marked decrease in the volume of liver metastases and the effect remained for 8 months (partial response). "
04/12/1996 - "Of 120 patients receiving a combination of rIL-2, rIFN-alpha 2 and 5-FU, 13 patients achieved a complete and 34 a partial remission (lung, liver, local relapse, bone, adrenal, pleural, and thyroid metastases; overall response 39%). "
|5.||Breast Neoplasms (Breast Cancer)
04/01/2015 - "The remarkable anticancer therapeutic efficacy with negligible toxicity profile of 5-FU NP makes it one of the possible alternative for the successful breast cancer therapy."
07/01/2010 - "5-FU is more effective in combination with the TS-reducing action of Rap, even for highly HER2-expressing breast cancer cells."
08/01/2000 - "The protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has proven in several studies an active and well tolerated treatment for advanced, pretreated breast cancer. "
06/01/2012 - "Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity."
01/01/1995 - "Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer."
|1.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)